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Abstract
Several approaches have been explored to eradicate HIV; however, a multigene vaccine appears to be the best
option, given their proven potential to elicit broad, effective responses in animal models. The Pr55Gag protein is an
excellent vaccine candidate in its own right, given that it can assemble into large, enveloped, virus-like particles
(VLPs) which are highly immunogenic, and can moreover be used as a scaffold for the presentation of other large
non-structural HIV antigens. In this study, we evaluated the potential of two novel chimaeric HIV-1 Pr55Gag-based
VLP constructs - C-terminal fusions with reverse transcriptase and a Tat::Nef fusion protein, designated GagRT and
GagTN respectively - to enhance a cellular response in mice when used as boost components in two types of het-
erologous prime-boost vaccine strategies. A vaccine regimen consisting of a DNA prime and chimaeric HIV-1 VLP
boosts in mice induced strong, broad cellular immune responses at an optimum dose of 100 ng VLPs. The
enhanced cellular responses induced by the DNA prime-VLP boost were two- to three-fold greater than two DNA
vaccinations. Moreover, a mixture of GagRT and GagTN VLPs also boosted antigen-specific CD8+ and CD4+ T-cell
responses, while VLP vaccinations only induced predominantly robust Gag CD4+ T-cell responses. The results
demonstrate the promising potential of these chimaeric VLPs as vaccine candidates against HIV-1.
Findings
The importance of a cellular immune response against
HIV-1 has been highlighted in several animal vaccine
trials [1,2], with an abundance of evidence suggesting
that an effective cellular immune response against HIV-
1 is able to control and suppress viraemia during pri-
mary and chronic HIV infections, and to provide long-
lasting protection [3-5]. Heterologous prime-boost vac-
cination has recently emerged as an effective means of
enhancing T-cell responses [6-8], and current research
suggests that HIV virus-like particles (VLPs) elicit a
superior cellular immune response against HIV in ani-
mal models when used as a boost component in a
prime-boost strategy [5,6]. In addition, previous studies
have indicated the importance of including more than
one HIV-1 proteins in a vaccine, due to the potential to
induce broader and possibly more effective immune
responses against HIV [9-11]. In this regard, Halsey
et al. [12] showed that HIV-1 Pr55Gag-based chimaeric
proteins with large C-terminal fusions both formed
VLPs, and significantly enhanced T-cell responses eli-
cited by a DNA vaccine to HIV-1 Gag and RT. The
accessory proteins Tat, Nef and RT - which contain sev-
eral prominent human cytotoxic T-lymphocyte (CTL)
epitopes - are of particular interest in HIV vaccines:
responses to Tat and Nef correlate with non-progression
of HIV infections and possible protection [9], while RT-
specific CTLs induce potent Th1 responses in mice,
when administered in low doses [13].
This study investigates immune responses induced by
chimaeric Gag VLPs incorporating RT and Tat-Nef
sequences (GagRT and GagTN) as vaccine boost candi-
dates to a DNA (pVRCgrttnC) priming vaccine expres-
sing subtype C non-myristylated p6-deleted Gag,
inactivated reverse transcriptase (RT), shuffled Tat (T)
and inactivated Nef (N), as a polyprotein [14]. We
further explored which combination of HIV-1 antigens
in a VLP would best augment cellular immune
responses induced by a complementary DNA vaccine,
using DNA/VLP prime-boost vaccine regimens.
The pVRCgrttnC DNA vaccine (1 mg/ml in PBS,
manufactured by Aldevron, Fargo, ND, USA) is based
on the pTHgrttnC vaccine described previously [14], but
has the pVRC backbone (provided by the Vaccine
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Research Centre of the National Institutes of Health,
Bethesda, Maryland, USA) in place of the pTH vector
[15]. GagRT VLPs were expressed from the HIV-1 sub-
type C Gag precursor Pr55Gag gene fused to the RT-
encoding sequence from grttnC, and GagTN VLPs from
a similar GagTatNef fusion [12]. Production of recombi-
nant baculovirus-expressed GagRT and GagTN VLPs
was optimized as described in Pillay et al. [16]. VLPs
were purified from 2.5 L of Sf9 cell culture supernatants
after 96 h incubation at 27°C. They were filtered
through a 0.45 μm CFP-4-E-4MA polysulfone mem-
brane capsule filter, and subsequently through a UFP-
300-C-4MA polyethersulfone membrane (MWCO = 300
kDa (both Amersham)). Both filtration steps were neces-
sary to remove cell debris and baculovirus contaminants
from VLP samples. VLPs were pelleted by ultracentrifu-
gation at 12 000 g for 60 min and re-suspended in PBS.
Purity of the resulting VLPs was assessed using SDS-
PAGE (Figure 1a and 1b). The presence of only the
appropriate-sized protein bands indicated that no
detectable contaminating material was present in the
VLP samples. Endotoxin levels were < 0.125 endotoxin
units per ml. Transmission electron microscopy (TEM)
using a Zeiss S1109 electron microscope showed charac-
teristic VLPs, albeit with a distribution of sizes [12].
Western blots probed with a 1:10 000 dilution of HIV-1
Gag p24 antibody (ARP432, NIBSC Centralised Facility
for AIDS reagents, MRC, UK) and developed with goat
anti-rabbit alkaline phosphatase conjugate (1:5 000;
Sigma) and 5-bromo-4-chloro-3-indolyl-phosphate/
nitroblue tetrazolium phosphatase substrate (BCIP/NBT;
KPL) were used to quantify the Gag content of the VLP
samples. The intensity of the Gag band in the VLP sam-
ples was compared to that of p17/p24-C standards
(ARP695.2. FIT Biotech) using densitometry (Figure 1c
and 1d).
Immunization of female BALB/c mice (8-10 weeks
old, five per group; approved by the UCT Animal
Research Ethics Committee, AEC No. 006-007) was by
injection of 50 μl of the DNA dose (100 μg DNA/100 μl
PBS) or 50 μl of the VLP dose (Gag protein dose in 100
μl PBS) into each hind leg muscle. Mice were primed
Figure 1 Purity and quantification of Gag in VLP preparations. Coomassie-stained SDS-PAGE gels of (a) GagTN VLP samples and (b) GagRT
VLP samples indicating the purity of the samples. Western blots of (c) GagTN VLP samples and (d) GagRT VLP samples probed with anti-Gag
p24 antibody. 0.1 and 0.01 indicate a 1:10 dilution and a 1:100 dilution, respectively, of VLPs loaded per lane. Western blots of Gag p17/p24
(p41) protein (24-240 ng) loaded per lane is indicated and the intensity of these bands was used to determine the Gag content of GagTN and
GagRT VLP samples. M = molecular weight marker and arrowheads indicate the migration distance of the respective chimaeric VLPs.
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with DNA on day 0 and boosted on day 28 with DNA
or GagRT or GagTN or a mix of GagRT and GagTN.
Initially, three doses of the chimaeric VLP boosts were
evaluated to determine the optimal dose necessary for
cellular immune response enhancement. These doses
were 50 ng, 100 ng or 200 ng of Gag per 100 μl PBS,
selected based on a previous DNA prime-VLP boost
study [17]. Once determined, the optimal dose was used
for the comparative mouse experiments. To test the
immunogenicity of GagRT or GagTN alone, mice were
left unprimed then vaccinated on day 28. Immune
responses were detected on day 40.
Harvested spleens were pooled from a group of mice
and isolated splenocytes were resuspended after erythro-
cyte lysis at 2 × 107 cells/ml R10 culture medium
(RPMI with 10% heat inactivated FCS, Gibco, containing
15 mM b-mercaptoethanol, 100 U/ml penicillin, and
100 μg/ml streptomycin). Splenocytes were cultured in
triplicate reactions with peptides (4 μg/ml) restricted to
BALB/c mouse epitopes in Gag (CD8 peptide
AMQMLKDTI; CD4(13) peptide NPPIPVGRIYKR-
WIILGLNK and CD4(17) peptide FRDYVDRFFKTL-
RAEQATQE), and RT (CD8 peptide VYYDPSKDLIA
and CD4 peptide PKVKQWPLTEVKIKALTAI) in IFN-g
and IL-2 ELISPOT assays in triplicate (BD™Biosciences)
[18]. Responses after subtraction of background in the
absence of peptides are reported as mean spot forming
units (sfu) ± standard deviation (SD) of the mean/106
splenocytes.
Of the three doses assessed, the most prominent cellu-
lar immune responses were observed using a 100 ng
VLP dose for the boost, with a two-fold differential in
IFN-g RT CD4 and CD8 responses for GagRT
(Figure 2a), and a 10-fold increase in the IFN-g Gag
CD8 response for GagTN (Figure 2b). The overall stron-
ger responses induced by the 100 ng dose indicated that
this was the optimum dose for both GagRT and GagTN
VLP boost vaccinations, and was used in subsequent
experiments.
After VLP-only vaccination with GagRT or GagTN,
Gag- and RT- specific CD4+ cells contributed 84% to
the cumulative IFN-g ELISPOT response for GagRT,
and 100% for GagTN. These VLPs also induced IL-2
Gag- and RT- specific responses (Figures 3 and 4).
These responses were considerably enhanced using the
heterologous prime-boost regimen.
The cumulative IFN-g ELISPOT responses to a prime
with DNA and boost with either GagRT or GagTN were
greater by 2.4- and 16-fold respectively than two DNA
vaccinations. The elicited responses after VLP boosts
were predominantly from CD4+ cells (Figures 3 and 4).
DNA prime/GagRT boost induced Gag and RT-specific
IL-2 producing CD8 and CD4 cells while DNA prime/
GagTN boost induced IL-2-producing Gag CD4 cells
only. These IL-2 responses were 3.4- and 4.6-fold above
that for two DNA vaccinations (Figures 3 and 4).
The DNA prime/mixed VLP boost vaccination
increased the cumulative Gag- and RT-specific IFN-g
Figure 2 Dose assessment for chimaeric VLP boost. Three groups of five BALB/c mice were primed on day 0 with the DNA vaccine
pVRCgrttnC and boosted with (a) GagRT or (b) GagTN on day 28. For all mouse groups spleens were harvested on day 40 and the splenocytes
were used in IFN-g ELISPOT and IL-2 ELISPOT assays with the indicated Gag and RT CD8 and CD4 peptides. Data represent results from one of
three representative experiments.
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Figure 3 Immunogenicity of GagRT VLPs. BALB/c mice were primed on day 0 with the DNA vaccine pVRCgrttnC then boosted on day 28
with the DNA vaccine (DNA+DNA group) or GagRT VLPs (DNA+GagRT group). A further group was left unprimed then vaccinated on day 28
with GagRT VLPs. For all mouse groups spleens were harvested on day 40 and splenocytes used in IFN-g ELISPOT and IL-2 ELISPOT assays with
the indicated Gag and RT CD8 and CD4 peptides. Cumulative ELISPOT responses to the vaccines are shown and are to the sum of responses to
the indicated peptides in the IFN-g ELISPOT or IL-2 ELISPOT assays with the indicated Gag and RT CD8 and CD4 peptides. Data represent results
from one of three representative experiments.
Figure 4 BALB/c mice were primed on day 0 with the DNA vaccine pVRCgrttnC then boosted on day 28 with DNA (DNA+DNA group)
or GagTN VLPs (DNA+GagTN group). A further group was left unprimed then vaccinated on day 28 with GagTN VLPs. For all mouse groups
spleens were harvested on day 40 and splenocytes used in IFN-g ELISPOT and IL-2 ELISPOT assays with the indicated Gag CD8 and CD4
peptides. Cumulative ELISPOT responses to the vaccines are shown and are to the sum of responses to the indicated peptides in the IFN-g
ELISPOT or IL-2 ELISPOT assays with the indicated Gag CD8 and CD4 peptides. Data represent results from one of three representative
experiments.
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response relative to two DNA vaccinations 4-fold, and
Gag- and RT-specific IL-2 response 2.8 fold. CD4+ cells
contributed 41% to the cumulative IFN-g and 31% to
IL-2 ELISPOT responses, respectively (Figure 5).
In conclusion, this study extends and confirms results
of our previous work in clearly showing that enhanced
cellular immune responses against Gag and RT result
when the chimaeric VLPs GagRT and GagTN are used
in mice in a DNA vaccine prime/VLP boost vaccination
regimen [12]. Novel results presented here include the
induction of predominantly specific CD4+ cells produ-
cing IFN-g and IL-2 by GagRT and GagTN vaccination
alone. The lack of response to these VLPs in our pre-
vious study is probably due to the VLP dose being 1/5
of that used in this study [12]. Surprisingly, this 5-fold
increase in GagRT dose did not increase the magnitude
of the reported DNA prime/GagRT boost response, sug-
gesting that only a low VLP dose is required for induc-
tion of recall cellular responses by primary vaccine-
induced memory cells.
In general, the magnitude of responses induced were
better using a single VLP boost, than with the mixed
VLP boost. This is possibly related to an antigen dose
effect, where above the optimum dose, antigen-specific
cellular immune responses decline [19]. The results of
the boost dose assessment (Figure 2) support this
hypothesis, as the 200 ng VLP boost (which is equiva-
lent to the mixed VLP dose administered) induced
much lower responses than the 100 ng dose. That being
said, the mixed VLP boost was able to elicit more pro-
portionate, cumulative CD4+ and CD8+ specific T-cell
responses. Expansion of specific CD4+ cells in response
to vaccination is important in that these cells play a key
role in activation of both B cells and CD8+ cells, and in
controlling CTL responses [20], and are linked to the
control of HIV-1 infection and replication [21,22]. How-
ever, it is the CD8+ cell response that is mainly respon-
sible for controlling the viral infection and suppressing
viraemia in HIV-infected individuals [23]. Hence, the
CD4+ and CD8+ cell boost observed with vaccination of
a VLP mix, and the finding that HIV-specific CD4+ and
CD8+ cells produce IFN-g and IL-2, are of strong signif-
icance. Collectively, the data shown here demonstrates
that chimaeric VLP boosts such as these are a promising
option for future HIV-1 vaccine studies.
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